Abivax SA, which is developing therapeutics for chronic inflammatory diseases, has appointed Sheldon Sloan as chief medical officer. Dr Sloan joints from Arena Pharmaceuticals Inc where he led the company’s programme for ulcerative colitis. Prior to this, he held successive leadership positions at Johnson & Johnson Inc in medical affairs, R&D and science policy. Dr Sloan holds an MD from Rush Medical College in Chicago and a Master of Bioethics from the University of Pennsylvania, both in the US.
Abivax announced the appointment on 17 February 2023.
Copyright 2023 Evernow Publishing Ltd